Epigenetic control of CCR5 transcript levels in immune cells and modulation by small molecules inhibitors

Journal of Cellular and Molecular Medicine

Volumn 16, Issue 8, 2012, Pages 1866-1877

  Wierda, Rutger J ^a   Kuipers, Hedwich F ^a,b,e   van Eggermond, Marja C J A ^a   Benard, Anne ^a   van Leeuwen, Jan C ^a   Carluccio, Silvia ^a   Geutskens, Sacha B ^a   Jukema, J Wouter ^a,c   Marquez, Victor E ^d   Quax, Paul H A ^a   van den Elsen, Peter J ^a,b  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c Durrer Center for Cardiogenetic Research   (Netherlands)

^d NATIONAL CANCER INSTITUTE   (United States)

^e STANFORD UNIVERSITY   (United States)

Author keywords

Bivalent chromatin; CCR5; Chromatin remodelling; DNA methylation; Histone modifications; Monocytes; Poised chromatin; T cells

Indexed keywords

CHEMOKINE RECEPTOR CCR5; CREB1 PROTEIN, HUMAN; CREM PROTEIN, HUMAN; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; CYCLIC AMP RESPONSIVE ELEMENT MODULATOR; HISTONE; ISOPROTEIN; MESSENGER RNA;

ARTICLE; BIOLOGICAL MODEL; CELL MEMBRANE; CHROMATIN IMMUNOPRECIPITATION; DNA METHYLATION; DRUG ANTAGONISM; DRUG EFFECT; GENETIC EPIGENESIS; GENETICS; HUMAN; IMMUNOMODULATION; LEUKEMIA CELL LINE; LYMPHOCYTE; METABOLISM; MOLECULAR LIBRARY; PROMOTER REGION; PROTEIN PROCESSING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

CELL MEMBRANE; CHROMATIN IMMUNOPRECIPITATION; CYCLIC AMP RESPONSE ELEMENT MODULATOR; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; DNA METHYLATION; EPIGENESIS, GENETIC; HISTONES; HUMANS; IMMUNOMODULATION; JURKAT CELLS; LYMPHOCYTES; MODELS, IMMUNOLOGICAL; PROMOTER REGIONS, GENETIC; PROTEIN ISOFORMS; PROTEIN PROCESSING, POST-TRANSLATIONAL; RECEPTORS, CCR5; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SMALL MOLECULE LIBRARIES;

EID: 84864386274     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2011.01482.x     Document Type: Article

References (62)

1. Bursill CA, Channon KM, Greaves DR. The role of chemokines in atherosclerosis: recent evidence from experimental models and population genetics. Curr Opin Lipidol. 2004; 15: 145-9.
2. Ribeiro S, Horuk R. The clinical potential of chemokine receptor antagonists. Pharmacol Ther. 2005; 107: 44-58.
3. Biber K, Zuurman MW, Dijkstra IM, et al Chemokines in the brain: neuroimmunology and beyond. Curr Opin Pharm. 2002; 2: 63-8.
4. Schober A. Chemokines in vascular dysfunction and remodeling. Arterioscler Thromb Vasc Biol. 2008; 28: 1950-9.
5. Wu L, Paxton WA, Kassam N, et al CCR5 levels and expression pattern correlate with infectability by macrophage-tropic HIV-1, in vitro. J Exp Med. 1997; 185: 1681-91.
6. Oswald-Richter K, Grill SM, Leelawong M, et al Identification of a CCR5-expressing T cell subset that is resistant to R5-tropic HIV infection. PLoS Path. 2007; 3: 0553-65.
7. Carrington M, Dean M, Martin MP, et al Genetics of HIV-1 infection: chemokine receptor CCR5 polymorphism and its consequences. Hum Mol Genet. 1999; 8: 1939-45.
8. Ebert LM, McColl SR. Up-regulation of CCR5 and CCR6 on distinct subpopulations of antigen-activated CD4+ T lymphocytes. J Immunol. 2002; 168: 65-72.
9. Mummidi S, Adams LM, VanCompernolle SE, et al Production of specific mRNA transcripts, usage of an alternate promoter, and octamer-binding transcription factors influence the surface expression levels of the HIV coreceptor CCR5 on primary T cells. J Immunol. 2007; 178: 5668-81.
10. Mummidi S, Ahuja SS, McDaniel BL, et al The human CC chemokine receptor 5 (CCR5) gene. Multiple transcripts with 5'-end heterogeneity, dual promoter usage, and evidence for polymorphisms within the regulatory regions and noncoding exons. J Biol Chem. 1997; 272: 30662-71.
11. Bleul CC, Wu L, Hoxie JA, et al The HIV coreceptors CXCR4 and CCR5 are differentially expressed and regulated on human T lymphocytes. Proc Natl Acad Sci USA. 1997; 94: 1925-30.
12. Guignard F, Combadiere C, Tiffany HL, et al Gene organization and promoter function for CC chemokine receptor 5 (CCR5). J Immunol. 1998; 160: 985-92.
13. van der Merwe PA, Davis SJ. The immunological synapse-a multitasking system. Science. 2002; 295: 1479-80.
14. Grakoui A, Bromley SK, Sumen C, et al The immunological synapse: a molecular machine controlling T cell activation. Science. 1999; 285: 221-7.
15. Rossi D, Zlotnik A. The biology of chemokines and their receptors. Annu Rev Immunol. 2000; 18: 217-42.
16. Serbina NV, Jia T, Hohl TM, et al Monocyte-mediated defense against microbial pathogens. Annu Rev Immunol. 2008; 26: 421-52.
17. Schmitz G, Leuthauser-Jaschinski K, Orso E. Are circulating monocytes as microglia orthologues appropriate biomarker targets for neuronal diseases?Cent Nerv Syst Agents Med Chem. 2009; 9: 307-30.
18. Chan WY, Kohsaka S, Rezaie P. The origin and cell lineage of microglia: new concepts. Brain Res Rev. 2007; 53: 344-54.
19. Hansson GK, Robertson AKL, Soderberg-Naucler C. Inflammation and atherosclerosis. Annu Rev Pathol. 2006; 1: 297-329.
20. Libby P. Inflammation in atherosclerosis. Nature. 2002; 420: 868-74.
21. Noseworthy JH, Lucchinetti C, Rodriguez M, et al Multiple sclerosis. N Engl J Med. 2000; 343: 938-52.
22. Zernecke A, Shagdarsuren E, Weber C. Chemokines in atherosclerosis: an update. Arterioscler Thromb Vasc Biol. 2008; 28: 1897-908.
23. Zernecke A, Liehn EA, Gao J-L, et al Deficiency in CCR5 but not CCR1 protects against neointima formation in atherosclerosis-prone mice: involvement of IL-10. Blood. 2006; 107: 4240-3.
24. Fox RJ, Kivisakk P, Fisher E, et al Multiple sclerosis: chemokine receptor expression on circulating lymphocytes in correlation with radiographic measures of tissue injury. Mult Scler. 2008; 14: 1036-43.
25. Trebst C, Konig F, Ransohoff R, et al CCR5 expression on macrophages/microglia is associated with early remyelination in multiple sclerosis lesions. Mult Scler. 2008; 14: 728-33.
26. Kuipers HF, Biesta PJ, Montagne LJ, et al CC chemokine receptor 5 gene promoter activation by the cyclic AMP response element binding transcription factor. Blood. 2008; 112: 1610-9.
27. Meyer TE, Habener JF. Cyclic adenosine 3′, 5′-monophosphate response element binding protein (CREB) and related transcription-activating deoxyribonucleic acid-binding proteins. Endocr Rev. 1993; 14: 269-90.
28. Jaenisch R, Bird A. Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals. Nat Genet. 2003; 33(Suppl): 245-54.
29. Jenuwein T, Allis CD. Translating the histone code. Science. 2001; 293: 1074-80.
30. Strahl BD, Allis CD. The language of covalent histone modifications. Nature. 2000; 403: 41-5.
31. Vaissiere T, Sawan C, Herceg Z. Epigenetic interplay between histone modifications and DNA methylation in gene silencing. Mutat Res. 2008; 659: 40-8.
32. Rice JC, Briggs SD, Ueberheide B, et al Histone methyltransferases direct different degrees of methylation to define distinct chromatin domains. Mol Cell. 2003; 12: 1591-8.
33. Cao R, Zhang Y. The functions of E(Z)/EZH2-mediated methylation of lysine 27 in histone H3. Curr Opin Genet Dev. 2004; 14: 155-64.
34. Schotta G, Lachner M, Sarma K, et al A silencing pathway to induce H3-K9 and H4-K20 trimethylation at constitutive heterochromatin. Genes Dev. 2004; 18: 1251-62.
35. Martin C, Zhang Y. The diverse functions of histone lysine methylation. Nat Rev Mol Cell Biol. 2005; 6: 838-49.
36. Wang P, Lin C, Smith ER, et al Global analysis of H3K4 methylation defines MLL family member targets and points to a role for MLL1-mediated H3K4 methylation in the regulation of transcriptional initiation by RNA polymerase II. Mol Cell Biol. 2009; 29: 6074-85.
37. Bernstein BE, Mikkelsen TS, Xie X, et al A bivalent chromatin structure marks key developmental genes in embryonic stem cells. Cell. 2006; 125: 315-26.
38. Bapat SA, Jin V, Berry N, et al Multivalent epigenetic marks confer microenvironment-responsive epigenetic plasticity to ovarian cancer cells. Epigenetics. 2010; 5: 716-29.
39. Holling TM, van der Stoep N, Quinten E, et al Activated human T cells accomplish MHC class II expression through T cell-specific occupation of class II transactivator promoter III. J Immunol. 2002; 168: 763-70.
40. Ubogu EE, Callahan MK, Tucky BH, et al CCR5 expression on monocytes and T cells: modulation by transmigration across the blood-brain barrier in vitro. Cell Immunol. 2006; 243: 19-29.
41. Stresemann C, Brueckner B, Musch T, et al Functional diversity of DNA methyltransferase inhibitors in human cancer cell lines. Cancer Res. 2006; 66: 2794-800.
42. Marquez VE, Barchi JJ, Jr., Kelley JA, et al Zebularine: a unique molecule for an epigenetically based strategy in cancer chemotherapy. The magic of its chemistry and biology. Nucleosides Nucleotides Nucl Acids. 2005; 24: 305-18.
43. Miranda TB, Cortez CC, Yoo CB, et al DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation. Mol Cancer Ther. 2009; 8: 1579-88.
44. Tan J, Yang X, Zhuang L, et al Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes Dev. 2007; 21: 1050-63.
45. Khan N, Jeffers M, Kumar S, et al Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. Biochem J. 2008; 409: 581-9.
46. Banerjee A, Pirrone V, Wigdahl B, et al Transcriptional regulation of the chemokine co-receptor CCR5 by the cAMP/PKA/CREB pathway. Biomed Pharmacother. 2011; 65: 293-7.
47. Moriuchi H, Moriuchi M, Fauci AS. Cloning and analysis of the promoter region of CCR5, a coreceptor for HIV-1 entry. J Immunol. 1997; 159: 5441-9.
48. Liu R, Zhao X, Gurney TA, et al Functional analysis of the proximal CCR5 promoter. AIDS Res Hum Retroviruses. 1998; 14: 1509-19.
49. De Gobbi M, Garrick D, Lynch M, et al Generation of bivalent chromatin domains during cell fate decisions. Epigenetics Chromatin. 2011; 4: 9.
50. Ke X-S, Qu Y, Cheng Y, et al Global profiling of histone and DNA methylation reveals epigenetic-based regulation of gene expression during epithelial to mesenchymal transition in prostate cells. BMC Genomics. 2010; 11: 669.
51. Holling TM, Bergevoet MWT, Wilson L, et al A role for EZH2 in silencing of IFN-gamma inducible MHC2TA transcription in uveal melanoma. J Immunol. 2007; 179: 5317-25.
52. Holling TM, Bergevoet MWT, Wierda RJ, et al Genetic and epigenetic control of the major histocompatibility complex class Ib gene HLA-G in trophoblast cell lines. Ann N Y Acad Sci. 2009; 1173: 538-44.
53. Gonzalgo ML, Hayashida T, Bender CM, et al The role of DNA methylation in expression of the p19/p16 locus in human bladder cancer cell lines. Cancer Res. 1998; 58: 1245-52.
54. Ten Haaf A, Franken L, Heymann C, et al Paradox of sonic hedgehog (SHH) transcriptional regulation: Alternative transcription initiation overrides the effect of downstream promoter DNA methylation. Epigenetics. 2011; 6: 465-77.
55. Noguchi T, Takeno S, Kimura Y, et al FHIT expression and hypermethylation in esophageal squamous cell carcinoma. Int J Mol Med. 2003; 11: 441-7.
56. Kondo Y, Shen L, Cheng AS, et al Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation. Nat Genet. 2008; 40: 741-50.
57. Yu Q. Cancer gene silencing without DNA hypermethylation. Epigenetics. 2008; 3: 315-7.
58. Cheng X, Blumenthal RM. Coordinated chromatin control: structural and functional linkage of DNA and histone methylation. Biochemistry. 2010; 49: 2999-3008.
59. Fuks F. DNA methylation and histone modifications: teaming up to silence genes. Curr Opin Genet Dev. 2005; 15: 490-5.
60. Gong X, Feng H, Zhang S, et al Increased expression of CCR5 in experimental autoimmune myocarditis and reduced severity induced by anti-CCR5 monoclonal antibody. J Mol Cell Cardiol. 2007; 42: 781-91.
61. Trebst C, Konig F, Ransohoff R, et al CCR5 expression on macrophages/microglia is associated with early remyelination in multiple sclerosis lesions. Mult Scler. 2008; 14: 728-33.
62. Moreno CS, Beresford GW, Louis-Plence P, et al CREB regulates MHC class II expression in a CIITA-dependent manner. Immunity. 1999; 10: 143-51.